Analysts hound Biogen with questions over Aduhelm's $56K price point as news of Alzheimer's OK ripples through global markets
It’s been nearly 24 hours since the FDA handed down its controversial decision to approve Biogen’s Aduhelm drug for Alzheimer’s disease, and reactions from around the industry are pouring in as analysts try to size up the ramifications of Monday’s news.
Biogen hosted an investor call Tuesday morning, providing a forum for a number of topics that have been top of mind. The call came as the news of Aduhelm’s approval in the US rippled through global markets, while $BIIB stock soared to around $380 apiece (up from $286 on Friday), as Biogen’s partners at Eisai seek new approvals in Asia.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 157,600+ biopharma pros reading Endpoints daily — and it's free.